HC Wainwright reissued their buy rating on shares of Opus Genetics (NASDAQ:IRD – Free Report) in a research note released on Tuesday morning,Benzinga reports. They currently have a $8.00 target price on the stock.
Opus Genetics Trading Down 7.3 %
Opus Genetics stock opened at $0.91 on Tuesday. The firm has a market capitalization of $29.16 million, a PE ratio of -0.83 and a beta of 0.28. The stock’s 50-day moving average price is $1.07. Opus Genetics has a 12-month low of $0.81 and a 12-month high of $1.56.
Opus Genetics (NASDAQ:IRD – Get Free Report) last released its quarterly earnings results on Monday, March 31st. The company reported ($1.27) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.93). Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 63.65%. The firm had revenue of $3.40 million for the quarter, compared to analysts’ expectations of $11.10 million. Research analysts anticipate that Opus Genetics will post -1.22 earnings per share for the current fiscal year.
About Opus Genetics
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
Recommended Stories
- Five stocks we like better than Opus Genetics
- ESG Stocks, What Investors Should Know
- D-Wave: Multiple Use Cases Emerge Following Quantum Supremacy
- How to Invest in Tech Stocks and Top Tech Stocks to Consider
- Amazon Falls Back to a Key Support Line: Here’s How to Play It
- Expert Stock Trading Psychology Tips
- Buffett Trims Equities, But Still Keeps Buying This Stock
Receive News & Ratings for Opus Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opus Genetics and related companies with MarketBeat.com's FREE daily email newsletter.
